|
This complaint was reopened in reference to (b)(4).Manufacturing site evaluation: manufacturing and quality control data the progav® was manufactured by a qualified employee in (b)(6) 2013.Deviations during assembly did not occur.The valve was sterilized by miethke and released for shipment after final inspection.The progav® has a normal pressure range of 0 to 20 cmh2o.The valve was inspected as article fv421t.All parameters have been inspected and approved during the manufacturing process.All parameters have been assessed as meeting specification.Device examination: the valve was received submersed in an unidentified liquid in the provided returnkit.Visual inspection: no significant deformations or damage to the valve were detected during the visual inspection.A measurement of the plane parallelism revealed a deformation of the outer housing of the progav® valve.Permeability test: a permeability test has shown that the valve is permeable with difficulty.Adjustment test: the progav® was tested and is not adjustable throughout the normal range.Braking force and brake function test: the brake functionality test has shown that the brake function is operational; however, the braking force cannot be measured due to the non-adjustability of the valve.Computer controlled test: to investigate the claim of over-drainage, the opening pressure was measured using a miethke computer controlled testing apparatus which simulates a cerebrospinal fluid flow.The results showed that the valve was not operating within the accepted tolerance in the horizontal position.Result: first, we performed a visual inspection of the progav®.No significant deformations or damage to the valve were detected during the visual inspection.However, a slight deviation was detected during the measurement of the plane parallelism.Next, the permeability, adjustability, as well as the brake functionally and brake force, of the valve were tested.The valve was permeable with difficulty, but was not adjustable.Furthermore, while the brake functionality was present, the braking force was unable to be measured due to the inability of the valve to hold a set pressure.Additionally, the opening pressure of the valve was out of tolerance.Finally, the valve was dismantled.A build-up of a substance (likely protein) was observed inside the valve.Based on the investigation, the claim of over-drainage and non-adjustability of the valve was substantiated.This was likely due to the deposits observed inside the valve.As described in scientific literature, the problem encountered is one of the known, inevitable risks of hydrocephalus (hc)-therapy by shunt implants.Manufacturing defects at the time of release have been excluded.The valve met all specifications of the final inspection when released from christoph miethke gmbh & co.Kg.No further regulatory actions are required.
|